Knowledge Library
Pain Discovery Assays & In Vivo Models
WuXi AppTec offers a comprehensive platform to evaluate lead candidates targeting various types of pain, including inflammatory, neuropathic, and fibromyalgia-like pain and osteoarthritis. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development, from target discovery to translational research and clinical biomarker testing and beyond. Full-scale molecular …Read More >
OncoWuXi Newsletter: June 2022
WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.
HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES
Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery
We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >
Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response
Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA damage of cancerous tissue or contributing to systemic antitumor immunity. The capacity of cancer cells to recognize DNA damages and initiate repair plays a major role in radio-resistance. Furthermore, the irradiated tumor cell death can …Read More >
Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies
Chronic neurodegenerative diseases encompass a variety of progressive conditions that affect neurons, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other forms of dementia. They are among the most common and challenging central nervous system (CNS) diseases. “Many companies had stopped their research program into neurodegenerative diseases, but now sophisticated technology advances have became more broadly …Read More >
Evaluation of the efficacy of ADC in vitro and in vivo
Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >